• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Invent Medic Sweden: Invent Medic launches Efemia bladder support in Norway together with the distributor Quintet

Read the release

Initially, Efemia will be available through Quintet's online store. In addition to this, the distribution agreement with Invent Medic enables the company to secure agreements with pharmacy chains and other entities in the retail market. In this area, Quintet has a close collaboration with the leading Norwegian pharmacy chain Apotek1, that offers a wide selection of medical assistance products in their pharmacies.

"It is exciting that we are now able to launch Efemia in Norway before the end of the year together with Quintet, which will enable us to help many Norwegian women to live their life to the fullest. Quintet's extensive experience in women's health-focused assistance products, combined with strong relations with health care and retail entities, makes them an excellent partner for us, says Invent Medic's CEO Karin Bryder.

"Efemia offers a unique and well-functioning solution for an important women's health problem, making it a great fit in our product portfolio. We have already presented the product at events in Bergen and Oslo with a positive response, and we have good reason to expect that the product will be well received by women with SUI as well as relevant health care entities in Norway," says Quintet's CEO Hanna Solberg.

Around 500,000 women in Norway are estimated to be using some kind of protection against urine leakage and are thereby potential regular Efemia users. The new Efemia distributor Quintet is focusing on assistance products in incontinence, pain relief and sexual health, which makes the company well-experienced in Efemia's product segment.